Hanall Biopharma Dividends and Buybacks
Dividend criteria checks 0/6
Hanall Biopharma does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-0.005%
Buyback Yield
| Total Shareholder Yield | -0.005% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Risks Still Elevated At These Prices As Hanall Biopharma Co., Ltd. (KRX:009420) Shares Dive 30%
Dec 09
Hanall Biopharma Co., Ltd.'s (KRX:009420) 30% Share Price Surge Not Quite Adding Up
Oct 14Calculating The Intrinsic Value Of Hanall Biopharma Co., Ltd. (KRX:009420)
Jun 26Getting In Cheap On Hanall Biopharma Co., Ltd. (KRX:009420) Is Unlikely
May 22There May Be Underlying Issues With The Quality Of Hanall Biopharma's (KRX:009420) Earnings
Mar 13Introducing Hanall BiopharmaLtd (KRX:009420), The Stock That Zoomed 103% In The Last Five Years
Feb 12What Kind Of Investors Own Most Of Hanall Biopharma Co.,Ltd (KRX:009420)?
Jan 25
Hanall Biopharma Co.,Ltd's (KRX:009420) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Jan 04Hanall BiopharmaLtd (KRX:009420) Is Growing Earnings But Are They A Good Guide?
Dec 14Here's Why We Think Hanall BiopharmaLtd (KRX:009420) Is Well Worth Watching
Nov 21Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if A009420's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if A009420's dividend payments have been increasing.
Dividend Yield vs Market
| Hanall Biopharma Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (A009420) | n/a |
| Market Bottom 25% (KR) | 1.2% |
| Market Top 25% (KR) | 4.0% |
| Industry Average (Pharmaceuticals) | 1.1% |
| Analyst forecast (A009420) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate A009420's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate A009420's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate A009420's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as A009420 has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 16:09 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hanall Biopharma Co., Ltd. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ka-hye Hong | Daishin Securities Co. Ltd. |
| Jonghyun Park | DAOL Investment & Securities Co., Ltd. |
| null null | DBS Bank Ltd |